<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398134</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-H2158-201</org_study_id>
    <secondary_id>2019-004902-85</secondary_id>
    <nct_id>NCT04398134</nct_id>
  </id_info>
  <brief_title>A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection</brief_title>
  <official_title>A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assembly Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assembly Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of
      ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in
      participants with chronic hepatitis B virus (HBV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">January 19, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 19, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Adverse Events</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Premature Treatment Discontinuation due to an Adverse Event</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Mean log10 HBV DNA</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough Plasma Concentration of ABI-H2158</measure>
    <time_frame>Predose on Day 1, Week 4, Week 48, and Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough-to-Peak Plasma Concentration Ratio of ABI-H2158</measure>
    <time_frame>Predose on Day 1 and Weeks 4, 48, and 72 and at pre-specified intervals after dosing on Day 1 and Weeks 2, 8, 12, 16, 20, 24, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Plasma Concentration of ETV</measure>
    <time_frame>Predose on Day 1, Week 4, Week 48, and Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough-to-Peak Plasma Concentration Ratio of ETV</measure>
    <time_frame>Predose on Day 1 and Weeks 4, 48, and 72 and at pre-specified intervals after dosing on Day 1 and Weeks 2, 8, 12, 16, 20, 24, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mean log10 HBV Pre-genomic RNA (pgRNA)</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Reduction in HBV DNA Below the Assay Lower Limit of Quantitation</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Reduction in HBV pgRNA Below the Assay Lower Limit of Quantitation</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Plasma HBV Surface Antigen (HBsAg)</measure>
    <time_frame>Baseline and up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Plasma HBV &quot;e&quot; Antigen (HBeAg)</measure>
    <time_frame>Baseline and up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Plasma HBV Core-related Antigen (HBcrAg)</measure>
    <time_frame>Baseline and up to 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Normal Serum Alanine Aminotransferase (ALT)</measure>
    <time_frame>Baseline and up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with HBV Core Protein Gene Sequence Variation Potentially Associated with Treatment Nonresponse</measure>
    <time_frame>Up to 96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>ABI-H2158 plus ETV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus ETV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-H2158</intervention_name>
    <description>3 X 100 mg tablets for oral administration</description>
    <arm_group_label>ABI-H2158 plus ETV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic the ABI-H2158 tablets</description>
    <arm_group_label>Placebo plus ETV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir (ETV)</intervention_name>
    <description>0.5 mg tablet for oral administration</description>
    <arm_group_label>ABI-H2158 plus ETV</arm_group_label>
    <arm_group_label>Placebo plus ETV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index of 18 - 36 kg/m^2 and body weight ≥45 kg

          -  HBeAg ≥500 IU/mL at Screening

          -  In good general health except for chronic HBV infection for ≥6 months documented, for
             example, by at least two measurements of HBsAg positivity and/or detectable HBV DNA ≥6
             months apart

          -  Lack of cirrhosis or advanced liver disease

        Exclusion Criteria:

          -  Prior treatment for chronic HBV infection with lamivudine, telbivudine, adefovir,
             standard of care nucleoside or nucleotide analogue (NrtI), HBV core inhibitors, or an
             investigational agent for HBV infection

          -  History or evidence of advanced liver disease or hepatic decompensation (including
             jaundice, ascites, portal hypertension, gastrointestinal bleeding, esophageal varices,
             hepatic encephalopathy)

          -  History or presence of clinically significant medical conditions requiring frequent
             medical management or pharmacologic or surgical treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katia Alves, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assembly Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Assembly Biosciences</last_name>
    <phone>833-509-4583</phone>
    <email>clinicaltrials@assemblybio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Coalition of Inclusive Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <zip>2105</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBV</keyword>
  <keyword>hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

